Sarepta Therapeutics Inc. shares skyrocketed 37.8% in Tuesday trade after the company released promising early results from a gene therapy program being developed for the rare degenerative disease Duchenne muscular dystrophy.Tuesday marked the stock’s second-largest percentage gain in over 20 years. Its largest-ever percentage gain came in September 2016, when Sarepta’s SRPT-5.67% first drug was approved by the Food and Drug Administration.The results, which were confined to the first three patients enrolled in the phase 1/2a study, showed improvements in micro-dystrophin, a shortened version of the dystrophin gene that is used in gene therapy. Individuals with DMD have a mutation in that gene, affecting their production of the protein dystrophin and thus their muscular development. The disease mostly affects boys and typically kills patients before the age of 30.......
So the above article shows that we don’t have to wait 6/9 months to release final results. The present DMD trial by ANP is an “Open Label study”... which means the interem results can be released at any time now..
IMO ...don’t expect the ANP so to go up only 37% to around 6/7cents....we’re looking at multiples of x 10 cents...Billions of $$ here for DMD with Sarepta then SPMS ... then other indications.. eg ASTHMA....
